Xiong et al., 2020 - Google Patents
IL‐10 induces MC3T3‐E1 cells differentiation towards osteoblastic fate in murine modelXiong et al., 2020
View PDF- Document ID
- 40626481368549115
- Author
- Xiong Y
- Yan C
- Chen L
- Endo Y
- Sun Y
- Zhou W
- Hu Y
- Hu L
- Chen D
- Xue H
- Mi B
- Liu G
- Publication year
- Publication venue
- Journal of cellular and molecular medicine
External Links
Snippet
Abstract Interleukin‐10 (IL‐10) displays well‐documented anti‐inflammatory effects, but its effects on osteoblast differentiation have not been investigated. In this study, we found IL‐10 negatively regulates microRNA‐7025‐5p (miR‐7025‐5p), the down‐regulation of which …
- 102000003814 Interleukin-10 0 title abstract description 82
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiong et al. | IL‐10 induces MC3T3‐E1 cells differentiation towards osteoblastic fate in murine model | |
| Xiong et al. | RETRACTED ARTICLE: M2 Macrophagy-derived exosomal miRNA-5106 induces bone mesenchymal stem cells towards osteoblastic fate by targeting salt-inducible kinase 2 and 3 | |
| Zhao et al. | Macrophage MSR1 promotes BMSC osteogenic differentiation and M2-like polarization by activating PI3K/AKT/GSK3β/β-catenin pathway | |
| Chen et al. | Mesenchymal stem cell-derived exosomal microRNA-136-5p inhibits chondrocyte degeneration in traumatic osteoarthritis by targeting ELF3 | |
| Liu et al. | GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation | |
| Park et al. | Zinc promotes osteoblast differentiation in human mesenchymal stem cells via activation of the cAMP-PKA-CREB signaling pathway | |
| Chen et al. | RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation | |
| Xu et al. | High‐dose TGF‐β1 impairs mesenchymal stem cell–mediated bone regeneration via Bmp2 inhibition | |
| Zhang et al. | Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism | |
| Xie et al. | PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis | |
| Zhang et al. | Anabolic bone formation via a site‐specific bone‐targeting delivery system by interfering with semaphorin 4D expression | |
| Alexander et al. | Regulation of DMD pathology by an ankyrin-encoded miRNA | |
| Zhou et al. | Melatonin up‐regulates bone marrow mesenchymal stem cells osteogenic action but suppresses their mediated osteoclastogenesis via MT2‐inactivated NF‐κB pathway | |
| Du et al. | CB2R attenuates intervertebral disc degeneration by delaying nucleus pulposus cell senescence through AMPK/GSK3β pathway | |
| Mi et al. | Methyltransferase‐like 3‐mediated N6‐methyladenosine modification of miR‐7212‐5p drives osteoblast differentiation and fracture healing | |
| Xi et al. | IGFBP‐2 directly stimulates osteoblast differentiation | |
| Kim et al. | DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling | |
| Wang et al. | Adrenomedullin 2 improves bone regeneration in type 1 diabetic rats by restoring imbalanced macrophage polarization and impaired osteogenesis | |
| Xu et al. | Small extracellular vesicle-mediated miR-320e transmission promotes osteogenesis in OPLL by targeting TAK1 | |
| Kong et al. | Conditioned media from endothelial progenitor cells cultured in simulated microgravity promote angiogenesis and bone fracture healing | |
| Lu et al. | The osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways | |
| Bo-ding et al. | MiRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy | |
| Liu et al. | eIF2α signaling regulates ischemic osteonecrosis through endoplasmic reticulum stress | |
| Liao et al. | Osteocyte mitochondria regulate angiogenesis of transcortical vessels | |
| Zauli et al. | TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors |